Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
Dec 15 (Reuters) - ABPRO Holdings Inc ABP.O:
ABPRO HOLDINGS ANNOUNCES SUBMISSION OF AN IND APPLICATION TO INITIATE A PHASE 1 CLINICAL TRIAL OF T CELL ENGAGER ABP-102/CT-P72 FOR HER2-POSITIVE CANCERS
ABPRO HOLDINGS INC - PHASE 1 TRIAL FOR HER2-POSITIVE CANCERS EXPECTED IN 1H 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.